ORIGINAL INVESTIGATION

Size: px
Start display at page:

Download "ORIGINAL INVESTIGATION"

Transcription

1 ORIGINAL INVESTIGATION Outcome of Stroke in Patients Undergoing Hemodialysis Joseph Mattana, MD; Charles Effiong, MD; Romesh Gooneratne, MD; Pravin C. Singhal, MD Background: While elevated levels of serum creatinine have been shown to be a risk factor for diminished survival after stroke, it is unknown how renal replacement therapy may affect the outcome. Methods: Strokes occurring in 26 consecutive patients undergoing hemodialysis at our institution were reviewed and clinical and laboratory variables and outcome were compared with those of patients who had a stroke but had normal renal function. Results: Twenty-four strokes in the patients undergoing hemodialysis were ischemic while only 2 were hemorrhagic. Virtually all the patients had hypertension, half had diabetes mellitus, and most had some prior evidence of cardiovascular disease at the time of their stroke. Fifty percent of the patients undergoing hemodialysis had a good outcome (defined as being discharged home) while the remainder had a poor outcome (defined as dying or being discharged to a nursing facility). The combined presence of hypertension and coronary artery disease had a sensitivity of 91.2% for identifying patients with a poor outcome, while male sex, the presence of coronary artery disease, and the combined presence of hypertension, coronary artery disease, and/or congestive heart failure had sensitivities greater than 80% but low specificity. The outcome of patients undergoing hemodialysis was comparable with that of a control group of patients who had a stroke but had normal renal function, although the length of hospital stay was greater (mean [±SEM] 29.8±6.4 days vs 12.7±1.1 days, respectively; P.01). Conclusions: Hospitalized patients undergoing hemodialysis in whom stroke occurs appear to have as good an outcome as that of patients with normal renal function, although they are hospitalized longer. In addition, certain clinical variables seem to be associated with a worse outcome. Aggressive measures to prevent and treat stroke seem as warranted for patients undergoing hemodialysis as for patients with normal renal function, although interventions to reduce the length of hospital stay are needed. Arch Intern Med. 1998;158: From the Division of Nephrology, Long Island Jewish Medical Center, New Hyde Park, NY, and the Long Island Campus for the Albert Einstein College of Medicine, Bronx, NY. CHRONIC RENAL failure appears to be a significant risk factor for the development of stroke, as well as other complications of accelerated cardiovascular disease. 1 While renal replacement therapy may ameliorate many of the metabolic derangements of end-stage renal disease as well as other variables, such as platelet dysfunction, it does not diminish the risk of cardiovascular disease, which remains substantially higher in this group than in the general population. 2-8 Some, in fact, have argued that hemodialysis may actually accelerate atherogenesis, although this is controversial Among the cardiovascular complications seen in patients with endstage renal disease, stroke is the third leading cause of death, ranking behind heart disease and infection. 12 In particular, several studies have reported an alarmingly high incidence of hemorrhagic stroke in patients undergoing hemodialysis These data have demonstrated an important role for renal disease in predisposing to stroke. While the presence of renal failure appears to have a significant impact on the development of stroke as well as other cardiovascular complications in both patients not receiving dialysis and those receiving dialysis, Friedman 16 has reported that patients with renal insufficiency who are not receiving dialysis have diminished survival after stroke. This study strongly suggests that renal insufficiency can not only impact the risk of stroke but can also affect the outcome as well. However, it is unknown how renal replacement therapy might affect the outcome of stroke, although it is plausible that it might help by controlling platelet dysfunction, fluid overload, and other variables. In the 537

2 PATIENTS AND METHODS With the aid of a computerized medical record search using the International Classification of Diseases, Ninth Revision (ICD-9) 17 discharge codes, we identified 26 consecutive patients receiving maintenance hemodialysis who had a discharge diagnosis of stroke at our institution over a 10- year period (January 1987 to December 1996). Two patients were admitted to other hospitals for their stroke and it is from there that we obtained their data. Maintenance hemodialysis was defined as a requirement for supportive dialysis therapy for at least 30 days and continuation of dialysis in the outpatient setting in accordance with the definition of the Health Care Financing Administration. 12 Patients received dialysis using single-pass machines with cellulose acetate hollow fiber dialyzers and standard tubing. There was no dialyzer reuse. Patients underwent dialysis 3 times weekly using bicarbonate or acetate-based dialysate solutions of standard composition. All dialysis machines were cleaned between treatments using standard methods. After human recombinant erythropoietin became generally available in 1989, the majority of our patients were treated with this agent. Clinical data, including age, race, sex, and the presence of diabetes mellitus, hypertension, coronary artery disease, congestive heart failure, left ventricular hypertrophy, cardiac dysrhythmia, and peripheral vascular disease, were recorded. All computed tomographic and/or magnetic resonance imaging scans of the brain, including follow-up examinations, were interpreted by an attending neuroradiologist. Existence of coronary artery disease was defined by 1 or more of the following criteria: prior myocardial infarction or angina, abnormal results on thallium stress testing, and/or documentation by cardiac catheterization. Congestive heart failure was considered to be present if patients had a clinical history consistent with congestive heart failure and/or if there was evidence of congestive heart failure on chest radiographs, echocardiograms, or nuclear ejection fraction studies. Left ventricular hypertrophy was diagnosed using standard electrocardiographic and/or echocardiographic criteria. A history of cardiac dysrhythmia was determined by review of patients medical records, including Holter monitor reports or cardiac rhythm recordings during prior hospitalizations. Peripheral vascular disease was considered present if there was a history of claudication, arterial bypass, gangrene, amputation, and/or abnormal findings of duplex or arteriographic studies. Blood pressure and laboratory data obtained before dialysis during the month prior to the stroke were recorded. Duration of stay in the hospital, disposition (discharge home [defined as a good outcome] or discharge to a nursing facility or death [defined as a poor outcome]), and the presence of a residual neurological deficit at the time of discharge were all recorded. A control group of 87 consecutive cases of stroke in hospitalized patients at our institution with normal renal function (defined as a serum creatinine level 124 mmol/l [1.4 mg/dl]) were examined as well. Continuous variables are reported as mean (±SEM). For comparison of continuous variables, an unpaired Student t test was used. To compare proportions of patients with or without a given finding, a Fisher exact test or the 2 test with Yates continuity correction was used as appropriate. Statistical significance was defined as P<.05. present study we compared the outcome of stroke in 26 consecutive patients undergoing hemodialysis at our institution with that of a control group of patients in whom stroke occurred but who had no renal failure, and we have attempted to identify variables associated with a poor outcome. RESULTS Twenty-six consecutive patients undergoing maintenance hemodialysis who developed stroke were identified and studied. Two of the patients had been admitted to another institution with stroke and these records were obtained. The population had a mean (±SEM) age of 65.3±2.4 years (range, years). African Americans and whites accounted for the majority of the patients. 17 In addition, there were 4 Chinese patients and 3 Hispanic patients. Eighteen of the 26 patients were men. Half of the population had diabetes mellitus and all but 1 patient had hypertension. Sixteen patients (61.5%) had a history of coronary artery disease. Congestive heart failure and left ventricular hypertrophy were both common as well, being present in 11 (42.3%) and 12 (46.1%) of the patients, respectively. A history of cardiac dysrhythmia was present in 12 (46.1%) of the patients. Seven of the patients (27%) had a previous transient ischemic attack or stroke prior to this event. The most common cause of end-stage renal disease in our patients was diabetic nephropathy in 11 (42.3%), while hypertension was the cause in 8 (30.8%). The remainder of the patients had end-stage renal disease secondary to other causes, including chronic interstitial nephritis, renal papillary necrosis, vasculitis, and administration of intravenous radiocontrast. The cause was unknown in 2 patients. Patients mean (±SEM) systolic blood pressure was 160.9±7.9 mm Hg, while mean diastolic blood pressure was 87.0±4.5 mm Hg. Laboratory studies disclosed the following mean (±SEM) values: serum sodium ion, 137.2±0.8 mmol/l; potassium, 4.8±0.2 mmol/l; serum urea nitrogen, 25.2±2.5 mmol/l (70.6±6.9 mg/dl); and creatinine, 875±71 µmol/l (9.9±0.8 mg/dl). Levels of serum albumin were decreased at 34±2 g/l and serum cholesterol levels were 5.30±0.33 mmol/l (204.8±12.8 mg/ dl). Serum aminotransferase levels were within normal limits overall, and mean hematocrit was 0.30±0.02. The types of strokes and outcomes are summarized in the following: 24 strokes (92.3%) were ischemic in origin, with only 2 hemorrhagic strokes occurring. Half of the patients were left with some neurological deficit (ratio of residual deficit, 13:13 or 50%). Thirteen (50%) of the patients were eventually discharged home while 7 (23.1%) went to a nursing home and 6 patients (23.1%) died in the hospital. The mean (±SEM) length of stay for patients who survived was 29.8±6.4 days. The sensitivi- 538

3 Table 1. Sensitivities, Specificities, and Odds Ratios for Selected Clinical Variables for Predicting Adverse Outcome After Stroke* Variable Sensitivity, % Specificity, % Odds Ratio Sex M F Diabetes mellitus Hypertension CAD CHF LVH Arrhythmia Hypertension and CAD Hypertension and CHF Hypertension and (CAD and/or CHF) *Sensitivity, specificity, and odds ratio for adverse outcome (discharge to nursing home or death) were calculated for clinical variables in hospitalized patients undergoing hemodialysis with stroke. CAD indicates coronary artery disease; CHF, congestive heart failure; and LVH, left ventricular hypertrophy. The presence or absence of CAD, CHF, LVH, and arrhythmia were determined as described in the Methods section. ties and specificities of clinical variables for poor outcome after stroke in these patients are summarized in Table 1. Among the variables, the combined presence of hypertension and coronary artery disease had a 91.7% sensitivity for identifying patients with a poor outcome, although the specificity was low. Male sex, the presence of coronary artery disease with or without hypertension, and the combined presence of hypertension, coronary artery disease, and/or congestive heart failure yielded sensitivities of greater than 80% for identifying patients with poor outcome, but had low specificity. Table 2 provides a comparison of outcomes between patients undergoing hemodialysis and patients with normal renal function in whom stroke occurred. There was a tendency for the control patients to be somewhat older than the patients receiving hemodialysis (70.5±1.2 years vs 65.3±2.7 years, respectively), although this did not meet statistical significance (P=.05). The proportions of male and female patients did not differ between the groups (P=.11), but the racial makeup of the groups differed significantly in that there was a greater proportion of African American patients in the hemodialysis group, consistent with the greater proportion of African Americans in the overall population receiving hemodialysis compared with the general US population. When outcomes were compared, the proportions of patients with a good outcome were virtually identical: 43 (49%) control patients and 13 (50%) patients undergoing hemodialysis. The remainder of patients were discharged either to a nursing facility or died, and there was no difference in these 2 outcomes between the 2 groups (Table 2). While the outcome was comparable between patients undergoing hemodialysis and those with normal renal function, there was a substantial difference in length of stay because the patients receiving hemodialysis required hospitalization for about twice the number of days (29.8±6.4 days vs 12.7±1.1 days, respectively; P.01). Table 2. Comparison of Outcome of Stroke in Patients Undergoing Hemodialysis and Controls With Normal Renal Function* Variable COMMENT Group Hemodialysis (n=26) Control (n=87) Mean (±SEM) age, y 65.3± ± Race, No. African American White 7 64 Hispanic Asian 4 2 Sex, No. M F 8 44 NS Disposition, No. Home Nursing Home 7 33 NS Died 6 11 Mean (±SEM) hospital stay, d 29.8± ± *The outcomes of strokes were compared between patients receiving hemodialysis and a group of 87 consecutive patients with stroke who had normal renal function as defined in the Methods section. Statistical comparisons between continuous variables were made using unpaired Studen t test. Comparisons between proportions were carried out using the 2 test as described in the Methods section. While previous studies have shown that elevated serum creatinine levels appear to place patients at greater risk for stroke as well as a poor outcome after stroke, it is unknown whether renal replacement therapy might affect such an outcome. Such data could have clinical utility because if it were known that stroke had a dismal outcome in patients undergoing hemodialysis, it would suggest that stroke should be regarded as a preterminal event and hence one could argue that aggressive therapy would perhaps not be indicated in that setting. Although hemodialysis ameliorates many of the metabolic disturbances of uremia, these patients remain at substantially higher risk of death from cardiovascular and cerebrovascular disease compared with the general population. 12 Thus, it does not appear that hemodialysis can attenuate the risk of vascular disease to any significant extent. While it has been suggested that hemodialysis itself might accelerate atherogenesis, it seems more likely that other risk factors, such as hypertension, diabetes mellitus, and hyperlipidemia, play a predominant role in this process Virtually all our patients who developed stroke could be considered as having been at increased risk for this event, with all but one having hypertension and/or some evidence of cardiovascular disease. Half our patients had diabetes mellitus. Hypertension is well known to be associated with an increased risk of stroke 15,17,18 ; therefore, it is not surprising that virtually all our patients with stroke had a history of hypertension. Iseki and Fukiyama 15 have shown in patients undergoing hemodialysis that hypertension is an important predictor of stroke. Therefore, it is clear from the current literature that for patients with renal insufficiency not requiring renal replacement therapy as well P 539

4 as patients undergoing hemodialysis, the risk of stroke is significantly greater compared with the general population and it remains the third leading cause of death in these patients. THE PRESENT DATA suggest that the outcome of stroke in patients undergoing hemodialysis may be as good as the outcome in those with normal renal function. While the patients in the control group were slightly older and one might argue that this worsened the outcome in this group, even if the difference in mean age of 5 years were significant, it is doubtful that such a small difference in age would completely negate any difference in stroke outcome that might exist. Given the very high prevalence of preexisting vascular disease in the group of patients undergoing hemodialysis, it seems likely that as a whole this group might be expected to have a worse outcome. Regarding the difference in racial makeup between the groups, it should be noted that the proportion of African American patients in our hemodialysis group is fairly representative of the general population undergoing hemodialysis in the United States. African Americans are also well known for having a higher incidence of end-stage renal disease. Therefore, this difference in racial composition between control and hemodialysis groups is not surprising. Furthermore, given the worse outcome reported for a variety of diseases in African American patients, it seems doubtful that the stroke outcome was as good in the patients undergoing hemodialysis as in the control patients because of a high proportion of African Americans in the hemodialysis group. While the patients undergoing hemodialysis appeared to have an outcome comparable with that of control patients who had normal renal function, there was a substantially longer period of hospitalization for these patients. Perhaps hospital care for such patients is more complex because of the frequent multitude of associated medical problems that make radiologic testing, drug administration, and other procedures more difficult and hazardous. Many of the patients undergoing hemodialysis developed complications, such as pneumonia, respiratory failure, sepsis, arrhythmia, and other problems, that probably contributed to the longer hospital stay. It would seem that given the reasonably good outcome of stroke in these patients, additional efforts would best be directed at finding interventions that can effectively and safely shorten their length of stay. Several variables demonstrated fair sensitivity in identifying patients undergoing hemodialysis with a poor outcome after stroke. In our patients factors such as male sex, coronary artery disease, and the presence of hypertension with coronary artery disease and/or congestive heart failure had fairly good sensitivities for identifying poor outcome, although the specificities were low. While more work is needed in large groups of patients undergoing hemodialysis with stroke to find predictors of poor outcome with high sensitivity and specificity, these data suggest that male sex in addition to the presence of atherosclerotic disease of other vascular beds portends a worse outcome. One somewhat atypical finding in our patients was that, in contrast to the very high proportion of hemorrhagic stroke reported by Iseki et al 14,15 and Onoyama et al, 13 our population of predominantly African American and white patients undergoing hemodialysis almost always had ischemic stroke. There are certainly reasons for concern that patients undergoing hemodialysis might be at increased risk of hemorrhagic stroke given their platelet dysfunction and need for systemic heparinization. Other reports have also raised fears that hemodialysis might impose an inordinate hemorrhagic stroke risk. 21,22 However, the general Japanese population has a significantly higher risk of hemorrhagic stroke compared with that of US and European populations, an increased risk in some series of as much as 10-fold By contrast, in the United States about 80% of strokes are ischemic rather than hemorrhagic. Therefore, it is plausible that the differences in the types of strokes experienced by different populations of patients undergoing hemodialysis are a reflection of the types of strokes prevalent in these different populations, although we cannot make definitive inferences regarding this based on our sample size. Furthermore, our findings suggesting comparable outcomes in patients undergoing hemodialysis and in control patients with stroke may have relevance only to hemodialysis populations with a predominance of ischemic stroke. The percentage of ischemic stroke in our patients undergoing hemodialysis appeared to be somewhat higher than in the general population (92.3% vs approximately 80%). This could be because of the high prevalence of atherosclerotic vascular disease, making a stroke more likely to be due to a vascular occlusive event rather than hemorrhage. However, caution must be exercised given our relatively small sample size. It is also unclear whether a significant difference actually exists because a difference in status of only a few of our patients could substantially change our proportion of ischemic strokes. Nonetheless, our data are consistent with a predominance of ischemic strokes. If hemodialysis does have a salutary impact on the outcome of stroke, it is not clear by what mechanism this may occur. Among a number of potential mechanisms, amelioration of platelet dysfunction (perhaps limiting the extent of stroke or conversion to hemorrhagic stroke) and control of extracellular fluid volume overload (perhaps lessening the risk of increased intracranial pressure or hemorrhage in contrast to the patient with renal failure who is not receiving dialysis) could minimize the risk of complications related to stroke and therefore improve the outcome, although this is highly speculative. In addition, these mechanisms could potentially lower what otherwise might have been a higher incidence of hemorrhagic stroke in these patients. If, indeed, patients undergoing hemodialysis have the potential to have as positive an outcome after stroke as patients without renal disease, the question arises whether aggressive therapies, including thrombolytic therapy, are indicated. Our data do not have implications regarding either the safety or efficacy of thrombolytic therapy and further studies are needed to resolve this important issue. 540

5 In summary, the present study suggests that while renal insufficiency predisposes to stroke and a poor outcome after stroke, patients undergoing hemodialysis may have the potential to do as well after stroke as patients with normal renal function. Hence, aggressive therapy and rehabilitation efforts in these patients seem indicated, as well as measures to reduce how long they stay in the hospital. Accepted for publication August 29, Reprints: Joseph Mattana, MD, Division of Nephrology, Long Island Jewish Medical Center, New Hyde Park, NY REFERENCES 1. Wannamethee SG, Shaper G, Perry IJ. Serum creatinine concentration and risk of cardiovascular disease: a possible marker for increased risk of stroke. Stroke. 1997;28: Parfrey PS. Cardiac and cerebrovascular disease in chronic uremia. Am J Kidney Dis. 1993;21: Rostand SG, Brunzell JD, Cannon RO III, Victor RG. Cardiovascular complications in renal failure. J Am Soc Nephrol. 1991;2: Lazarus JM, Lowrie EG, Hampers CL, Merrill JP. Cardiovascular disease in uremic patients on hemodialysis. Kidney Int. 1975;7(suppl):S167-S Rostand SG, Gretes JC, Kirk KA, Rutsky EA, Andreoli TE. Ischemic heart disease in patients with uremia undergoing maintenance hemodialysis. Kidney Int. 1979; 16: Kronenberg F, Kathrein H, Konig P, et al. Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol. 1994;14: Rossi A, Bonfante L, Giacomini A, et al. Carotid artery lesions in patients with nondiabetic chronic renal failure. Am J Kidney Dis. 1996;27: Ma KW, Greene EL, Rail L. Cardiovascular risk factors in chronic renal failure and hemodialysis populations. Am J Kidney Dis. 1992;19: Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged hemodialysis. N Engl J Med. 1974;290: Lundin AP, Friedman EA. Vascular consequences of maintenance hemodialysis: an unproven case. Nephron. 1978;21: Burke JF, Francos GC, Moore LL, Cho SY, Lasker N. Accelerated atherosclerosis in chronic hemodialysis patients: another look. Nephron. 1978;21: United States Renal Data System. USRDS 1994 Annual Data Report. Bethesda, Md: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health; Onoyama K, Kumagai H, Miishima T, et al. Incidence of strokes and its prognosis in patients on maintenance hemodialysis. Jpn Heart J. 1986;27: Iseki K, Kinjo K, Kimura Y, Osawa A, Fukiyama K. Evidence of high risk of cerebral hemorrhage in chronic dialysis patients. Kidney Int. 1993;44: Iseki K, Fukiyama K. Predictors of stroke in patients receiving chronic hemodialysis. Kidney Int. 1996;50: Friedman PJ. Serum creatinine: an independent predictor of survival after stroke. J Int Med Res. 1991;229: World Health Organization. International Classification of Diseases, Ninth Revision (ICD-9). Geneva, Switzerland: World Health Organization; Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray D, Barre PE. Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int. 1996;49: Strandgaard S, Paulson OB. Cerebrovascular consequences of hypertension. Lancet. 1994;344: Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet. 1995;346: Weber DL, Reagan T, Leeds M. Intracerebral hemorrhage during hemodialysis. N Y State J Med. 1972;72: Chachati A, Dechenne C, Godon JP. Increased incidence of cerebral hemorrhage mortality in patients with analgesic nephropathy on hemodialysis. Nephron. 1987;45: Robins M, Baum HM. The national survey of stroke incidence. Stroke. 1981;12 (suppl 1): Ueda K, Omae T, Hirota Y, et al. Decreasing trend in incidence and mortality from stroke in Hisayama residents, Japan. Stroke. 1981;12: Tanaka H, Ueda Y, Hayashi M, et al. Risk factors for cerebral hemorrhage and cerebral infarction in a Japanese rural community. Stroke. 1982;13: Correction Error in Reference List. In the article titled Cost-effectiveness of Noninvasive Diagnostic Aids in Suspected Pulmonary Embolism, published in the November 10, 1997, issue of the ARCHIVES (Arch Intern Med. 1997;157: ), erroneous text inadvertently appears in the beginning of reference 10 on page The reference should begin with the author name of Bounameaux H. The journal regrets the error. 541

Silent cerebral infarction predicts vascular events in hemodialysis patients

Silent cerebral infarction predicts vascular events in hemodialysis patients Kidney International, Vol. 67 (2005), pp. 2434 2439 Silent cerebral infarction predicts vascular events in hemodialysis patients TOSHIHIDE NAGANUMA,JUNJI UCHIDA,KENJI TSUCHIDA, YOSHIAKI TAKEMOTO, SHINJI

More information

Incidence of Strokes and Its Prognosis in Patients on Maintenance Hemodialysis

Incidence of Strokes and Its Prognosis in Patients on Maintenance Hemodialysis Incidence of Strokes and Its Prognosis in Patients on Maintenance Hemodialysis Kaoru ONOYAMA, M.D., Harumitsu KUMAGAI, M.D., Tiaki MIISHIMA, M.D., Hiroshi TSURUDA, M.D., Suguru TOMOOKA, M.D., Kenichi MOTOMURA,

More information

Chapter 4: Cardiovascular Disease in Patients With CKD

Chapter 4: Cardiovascular Disease in Patients With CKD Chapter 4: Cardiovascular Disease in Patients With CKD Introduction Cardiovascular disease is an important comorbidity for patients with chronic kidney disease (CKD). CKD patients are at high-risk for

More information

Left ventricular hypertrophy: why does it happen?

Left ventricular hypertrophy: why does it happen? Nephrol Dial Transplant (2003) 18 [Suppl 8]: viii2 viii6 DOI: 10.1093/ndt/gfg1083 Left ventricular hypertrophy: why does it happen? Gerard M. London Department of Nephrology and Dialysis, Manhes Hospital,

More information

Chapter 4: Cardiovascular Disease in Patients With CKD

Chapter 4: Cardiovascular Disease in Patients With CKD Chapter 4: Cardiovascular Disease in Patients With CKD The prevalence of cardiovascular disease is 68.8% among patients aged 66 and older who have CKD, compared to 34.1% among those who do not have CKD

More information

Chapter 4: Cardiovascular Disease in Patients with CKD

Chapter 4: Cardiovascular Disease in Patients with CKD Chapter 4: Cardiovascular Disease in Patients with CKD The prevalence of cardiovascular disease (CVD) was 65.8% among patients aged 66 and older who had chronic kidney disease (CKD), compared to 31.9%

More information

The CARI Guidelines Caring for Australasians with Renal Impairment. Biochemical Targets. Calcium GUIDELINES

The CARI Guidelines Caring for Australasians with Renal Impairment. Biochemical Targets. Calcium GUIDELINES Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Biochemical Targets CARMEL HAWLEY (Woolloongabba, Queensland) GRAHAME ELDER (Westmead, New South Wales) Calcium GUIDELINES

More information

Chapter 2: Identification and Care of Patients With Chronic Kidney Disease

Chapter 2: Identification and Care of Patients With Chronic Kidney Disease Chapter 2: Identification and Care of Patients With Chronic Kidney Disease Introduction The examination of care in patients with chronic kidney disease (CKD) is a significant challenge, as most large datasets

More information

Protecting the heart and kidney: implications from the SHARP trial

Protecting the heart and kidney: implications from the SHARP trial Cardiology Update, Davos, 2013: Satellite Symposium Protecting the heart and kidney: implications from the SHARP trial Colin Baigent Professor of Epidemiology CTSU, University of Oxford S1 First CTT cycle:

More information

Epidemiologic and clinical comparison of renal artery stenosis in black patients and white patients

Epidemiologic and clinical comparison of renal artery stenosis in black patients and white patients ORIGINAL ARTICLES Epidemiologic and clinical comparison of renal artery stenosis in black patients and white patients Andrew C. Novick, MD, Safwat Zald, MD, David Goldfarb, MD, and Ernest E. Hodge, MD,

More information

CAD in Chronic Kidney Disease. Kuang-Te Wang

CAD in Chronic Kidney Disease. Kuang-Te Wang CAD in Chronic Kidney Disease Kuang-Te Wang InIntroduction What I am going to talk about: CKD and its clinical impact on CAD Diagnosis of CAD in CKD PCI / Revasc Outcomes in CKD CKD PCI CAD Ohtake T,

More information

Clinical Features and Subtypes of Ischemic Stroke Associated with Peripheral Arterial Disease

Clinical Features and Subtypes of Ischemic Stroke Associated with Peripheral Arterial Disease Cronicon OPEN ACCESS EC NEUROLOGY Research Article Clinical Features and Subtypes of Ischemic Stroke Associated with Peripheral Arterial Disease Jin Ok Kim, Hyung-IL Kim, Jae Guk Kim, Hanna Choi, Sung-Yeon

More information

Chapter IV. Patient Characteristics at the Start of ESRD: Data from the HCFA Medical Evidence Form

Chapter IV. Patient Characteristics at the Start of ESRD: Data from the HCFA Medical Evidence Form Annual Data Report Patient Characteristics from HCFA Medical Evidence Form Chapter IV Patient Characteristics at the Start of ESRD: Data from the HCFA Medical Evidence Form Key Words: Medical Evidence

More information

POOR LONG-TERM SURVIVAL AFTER ACUTE MYOCARDIAL INFARCTION AMONG PATIENTS ON LONG-TERM DIALYSIS

POOR LONG-TERM SURVIVAL AFTER ACUTE MYOCARDIAL INFARCTION AMONG PATIENTS ON LONG-TERM DIALYSIS POOR LONG-TERM SURVIVAL AFTER ACUTE MYOCARDIAL INFARCTION AMONG PATIENTS ON LONG-TERM DIALYSIS CHARLES A. HERZOG, M.D., JENNIE Z. MA, PH.D., AND ALLAN J. COLLINS, M.D. ABSTRACT Background Cardiovascular

More information

Chapter 5: Acute Kidney Injury

Chapter 5: Acute Kidney Injury Chapter 5: Acute Kidney Injury Introduction In recent years, acute kidney injury (AKI) has gained increasing recognition as a major risk factor for the development of chronic kidney disease (CKD). The

More information

Prevalence of cardiovascular damage in early renal disease

Prevalence of cardiovascular damage in early renal disease Nephrol Dial Transplant 2001) 16 wsuppl 2x: 7±11 Prevalence of cardiovascular damage in early renal disease Adeera Levin University of British Columbia, Renal Insuf ciency Clinic, Vancouver, Canada Abstract

More information

Effects of Kidney Disease on Cardiovascular Morbidity and Mortality

Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs

More information

The CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors

The CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker

More information

Echocardiography analysis in renal transplant recipients

Echocardiography analysis in renal transplant recipients Original Research Article Echocardiography analysis in renal transplant recipients S.A.K. Noor Mohamed 1*, Edwin Fernando 2, 1 Assistant Professor, 2 Professor Department of Nephrology, Govt. Stanley Medical

More information

Asthma J45.20 Mild, uncomplicated J45.21 Mild, with (acute) exacerbation J45.22 Mild, with status asthmaticus

Asthma J45.20 Mild, uncomplicated J45.21 Mild, with (acute) exacerbation J45.22 Mild, with status asthmaticus A Fib & Flutter I48.0 Paroxysmal atrial fibrillation I48.1 Persistent atrial fibrillation I48.2 Chronic atrial fibrillation I48.3 Typical atrial flutter Asthma J45.20 Mild, uncomplicated J45.21 Mild, with

More information

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,

More information

Table S1: Diagnosis and Procedure Codes Used to Ascertain Incident Hip Fracture

Table S1: Diagnosis and Procedure Codes Used to Ascertain Incident Hip Fracture Technical Appendix Table S1: Diagnosis and Procedure Codes Used to Ascertain Incident Hip Fracture and Associated Surgical Treatment ICD 9 Code Descriptions Hip Fracture 820.XX Fracture neck of femur 821.XX

More information

HEART AND SOUL STUDY OUTCOME EVENT - MORBIDITY REVIEW FORM

HEART AND SOUL STUDY OUTCOME EVENT - MORBIDITY REVIEW FORM REVIEW DATE REVIEWER'S ID HEART AND SOUL STUDY OUTCOME EVENT - MORBIDITY REVIEW FORM : DISCHARGE DATE: RECORDS FROM: Hospitalization ER Please check all that may apply: Myocardial Infarction Pages 2, 3,

More information

Contrast Induced Nephropathy

Contrast Induced Nephropathy Contrast Induced Nephropathy O CIAKI refers to an abrupt deterioration in renal function associated with the administration of iodinated contrast media O CIAKI is characterized by an acute (within 48 hours)

More information

Comorbidity or medical history Existing diagnoses between 1 January 2007 and 31 December 2011 AF management care AF symptoms Tachycardia

Comorbidity or medical history Existing diagnoses between 1 January 2007 and 31 December 2011 AF management care AF symptoms Tachycardia Supplementary Table S1 International Classification of Disease 10 (ICD-10) codes Comorbidity or medical history Existing diagnoses between 1 January 2007 and 31 December 2011 AF management care I48 AF

More information

2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.

2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension. 2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension Writing Group: Background Hypertension worldwide causes 7.1 million premature

More information

Chapter 9: Cardiovascular Disease in Patients With ESRD

Chapter 9: Cardiovascular Disease in Patients With ESRD Chapter 9: Cardiovascular Disease in Patients With ESRD Cardiovascular disease is common in adult ESRD patients, with atherosclerotic heart disease and congestive heart failure being the most common conditions

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Inohara T, Xian Y, Liang L, et al. Association of intracerebral hemorrhage among patients taking non vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital

More information

Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients

Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients 1/5 This site became the new ClinicalTrials.gov on June 19th. Learn more. We will be updating this site in phases. This allows us to move faster and to deliver better services. Show less IMPORTANT: Listing

More information

USRDS UNITED STATES RENAL DATA SYSTEM

USRDS UNITED STATES RENAL DATA SYSTEM USRDS UNITED STATES RENAL DATA SYSTEM Chapter 9: Cardiovascular Disease in Patients With ESRD Cardiovascular disease is common in ESRD patients, with atherosclerotic heart disease and congestive heart

More information

USRDS UNITED STATES RENAL DATA SYSTEM

USRDS UNITED STATES RENAL DATA SYSTEM USRDS UNITED STATES RENAL DATA SYSTEM Chapter 2: Identification and Care of Patients With CKD Over half of patients from the Medicare 5 percent sample have either a diagnosis of chronic kidney disease

More information

Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) Long Term Outcomes

Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) Long Term Outcomes Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with (MOMENTUM 3) Long Term Outcomes Mandeep R. Mehra, MD, Daniel J. Goldstein, MD, Nir Uriel, MD, Joseph

More information

Medicare and Medicaid Payments

Medicare and Medicaid Payments and Payments The following table includes information about payments made by and for the 17 medical conditions/surgical procedures included in this Hospital Performance Report. This analysis is based on

More information

Why is co-morbidity important for cancer patients? Di Riley Associate Director Clinical Outcomes Programme

Why is co-morbidity important for cancer patients? Di Riley Associate Director Clinical Outcomes Programme Why is co-morbidity important for cancer patients? Di Riley Associate Director Clinical Outcomes Programme Co-morbidity in cancer Definition:- Co-morbidity is a disease or illness affecting a cancer patient

More information

Elevated risk of stroke among patients with end-stage renal disease

Elevated risk of stroke among patients with end-stage renal disease Kidney International, Vol. 64 (2003), pp. 603 609 Elevated risk of stroke among patients with end-stage renal disease STEPHEN L. SELIGER, DANIEL L. GILLEN, W.T. LONGSTRETH, JR., BRYAN KESTENBAUM, and CATHERINE

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines

More information

Nephrology Dialysis Transplantation

Nephrology Dialysis Transplantation Nephrol Dial Transplant ( 1997) 12: 718 723 Original Article Nephrology Dialysis Transplantation Onset of coronary artery disease prior to initiation of haemodialysis in patients with end-stage renal disease

More information

Nonembolic Occlusion of the Middle Cerebral and Carotid Arteries- A Comparison of Predisposing Factors

Nonembolic Occlusion of the Middle Cerebral and Carotid Arteries- A Comparison of Predisposing Factors Nonembolic Occlusion of the Middle Cerebral and Carotid Arteries- A Comparison of Predisposing Factors BY SIEGFRIED HEYDEN, M.D.,* ALBERT HEYMAN, M.D.,f AND JOHN A. GOREE, M.D4 Abstract-: Nonembolic Occlusion

More information

Cardiovascular Disorders Lecture 3 Coronar Artery Diseases

Cardiovascular Disorders Lecture 3 Coronar Artery Diseases Cardiovascular Disorders Lecture 3 Coronar Artery Diseases By Prof. El Sayed Abdel Fattah Eid Lecturer of Internal Medicine Delta University Coronary Heart Diseases It is the leading cause of death in

More information

Canadian Best Practice Recommendations for Stroke Care. (Updated 2008) Section # 3 Section # 3 Hyperacute Stroke Management

Canadian Best Practice Recommendations for Stroke Care. (Updated 2008) Section # 3 Section # 3 Hyperacute Stroke Management Canadian Best Practice Recommendations for Stroke Care (Updated 2008) Section # 3 Section # 3 Hyperacute Stroke Management Reorganization of Recommendations 2008 2006 RECOMMENDATIONS: 2008 RECOMMENDATIONS:

More information

Tennessee Department of Health in collaboration with Tennessee State University and University of Tennessee Health Science Center

Tennessee Department of Health in collaboration with Tennessee State University and University of Tennessee Health Science Center Tennessee Department of Health in collaboration with Tennessee State University and University of Tennessee Health Science Center 2006 Tennessee Department of Health 2006 ACKNOWLEDGEMENTS CONTRIBUTING

More information

Statistical Fact Sheet Populations

Statistical Fact Sheet Populations Statistical Fact Sheet Populations At-a-Glance Summary Tables Men and Cardiovascular Diseases Mexican- American Males Diseases and Risk Factors Total Population Total Males White Males Black Males Total

More information

HTA ET DIALYSE DR ALAIN GUERIN

HTA ET DIALYSE DR ALAIN GUERIN HTA ET DIALYSE DR ALAIN GUERIN Cardiovascular Disease Mortality General Population vs ESRD Dialysis Patients 100 Annual CVD Mortality (%) 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age

More information

4. Which survey program does your facility use to get your program designated by the state?

4. Which survey program does your facility use to get your program designated by the state? TRAUMA SURVEY Please complete one survey for each TCD designation you have in your facility. There would be a maximum of three surveys completed if your facility was designated as a trauma, stroke and

More information

NIH Public Access Author Manuscript Transplant Proc. Author manuscript; available in PMC 2010 July 14.

NIH Public Access Author Manuscript Transplant Proc. Author manuscript; available in PMC 2010 July 14. NIH Public Access Author Manuscript Published in final edited form as: Transplant Proc. 1990 February ; 22(1): 17 20. The Effects of FK 506 on Renal Function After Liver Transplantation J. McCauley, J.

More information

On Referral to our Unit

On Referral to our Unit Case Presentation By Samah Ibrahim Abdel Meguid Idris, MD Internal Medicine & Nephrology Consultant Head of Hemodialysis Unit Ahmed Maher Hospital, Alexandria Patient Data MEA 27-year-old male patient

More information

Chapter 8: Cardiovascular Disease in Patients with ESRD

Chapter 8: Cardiovascular Disease in Patients with ESRD Chapter 8: Cardiovascular Disease in Patients with ESRD Cardiovascular disease (CVD) is common in adult end-stage renal disease (ESRD) patients, with coronary artery disease (CAD) and heart failure (HF)

More information

Why is co-morbidity important for cancer patients? Michael Chapman Research Programme Manager

Why is co-morbidity important for cancer patients? Michael Chapman Research Programme Manager Why is co-morbidity important for cancer patients? Michael Chapman Research Programme Manager Co-morbidity in cancer Definition:- Co-morbidity is a disease or illness affecting a cancer patient in addition

More information

Cardiovascular Disease

Cardiovascular Disease Cardiovascular Disease Chapter 15 Introduction Cardiovascular disease (CVD) is the leading cause of death in the U.S. One American dies from CVD every 33 seconds Nearly half of all Americans will die from

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bucholz EM, Butala NM, Ma S, Normand S-LT, Krumholz HM. Life

More information

State Profile for FY 2018 for Dialysis Patients and Facilities - STATE SAMPLE

State Profile for FY 2018 for Dialysis Patients and Facilities - STATE SAMPLE Dear State Surveyor: State Profile for FY 2018 for Dialysis Patients and Facilities - STATE SAMPLE This report is designed to provide a comparative summary of treatment patterns and patient outcomes for

More information

TREAT THE KIDNEY TO SAVE THE HEART. Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009

TREAT THE KIDNEY TO SAVE THE HEART. Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009 TREAT THE KIDNEY TO SAVE THE HEART Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009 1 ESRD Prevalent Rates in 1996 per million population December

More information

Cardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center

Cardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Cardiovascular Disease in CKD Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Objectives Describe prevalence for cardiovascular disease in CKD

More information

Preoperative Serum Bicarbonate Levels Predict Acute Kidney Iinjry after Cardiac Surgery

Preoperative Serum Bicarbonate Levels Predict Acute Kidney Iinjry after Cardiac Surgery International Journal of ChemTech Research CODEN (USA): IJCRGG, ISSN: 0974-4290, ISSN(Online):2455-9555 Vol.11 No.06, pp 203-208, 2018 Preoperative Serum Bicarbonate Levels Predict Acute Kidney Iinjry

More information

Published trials point to a detrimental relationship

Published trials point to a detrimental relationship ANEMIA, CHRONIC KIDNEY DISEASE, AND CARDIOVASCULAR DISEASE: THE CLINICAL TRIALS Steven Fishbane, MD* ABSTRACT Clinical trials have shown a strong detrimental relationship among anemia, chronic kidney disease

More information

JUSTUS WARREN TASK FORCE MEETING DECEMBER 05, 2012

JUSTUS WARREN TASK FORCE MEETING DECEMBER 05, 2012 SAMUEL TCHWENKO, MD, MPH Epidemiologist, Heart Disease & Stroke Prevention Branch Chronic Disease & Injury Section; Division of Public Health NC Department of Health & Human Services JUSTUS WARREN TASK

More information

WHI Form Report of Cardiovascular Outcome Ver (For items 1-11, each question specifies mark one or mark all that apply.

WHI Form Report of Cardiovascular Outcome Ver (For items 1-11, each question specifies mark one or mark all that apply. WHI Form - Report of Cardiovascular Outcome Ver. 6. COMMENTS To be completed by Physician Adjudicator Date Completed: - - (M/D/Y) Adjudicator Code: OMB# 095-044 Exp: 4/06 -Affix label here- Clinical Center/ID:

More information

10/8/2018. Lecture 9. Cardiovascular Health. Lecture Heart 2. Cardiovascular Health 3. Stroke 4. Contributing Factor

10/8/2018. Lecture 9. Cardiovascular Health. Lecture Heart 2. Cardiovascular Health 3. Stroke 4. Contributing Factor Lecture 9 Cardiovascular Health 1 Lecture 9 1. Heart 2. Cardiovascular Health 3. Stroke 4. Contributing Factor 1 The Heart Muscular Pump The Heart Receives blood low pressure then increases the pressure

More information

Hypertensives Emergency and Urgency

Hypertensives Emergency and Urgency Hypertensives Emergency and Urgency Budi Yuli Setianto Cardiology Divisision Department of Internal Medicine Faculty of Medicine UGM Sardjito Hospital Yogyakarta Background USA: Hypertension is 30% of

More information

Data Fact Sheet. Congestive Heart Failure in the United States: A New Epidemic

Data Fact Sheet. Congestive Heart Failure in the United States: A New Epidemic National Heart, Lung, and Blood Institute Data Fact Sheet Congestive Heart Failure National Heart, Lung, and Blood Institute National Institutes of Health Data Fact Sheet Congestive Heart Failure in the

More information

SUPPLEMENTAL MATERIAL

SUPPLEMENTAL MATERIAL SUPPLEMENTAL MATERIAL Table S1: Number and percentage of patients by age category Distribution of age Age

More information

Why has the gross mortality of dialysis patients increased in Japan?

Why has the gross mortality of dialysis patients increased in Japan? Kidney International, Vol. 57, Suppl. 74 (2000), pp. S-60 S-65 Why has the gross mortality of dialysis patients increased in Japan? MORTALITY TAKASHI AKIBA, SHIGERU NAKAI, TORU SHINZATO, CHIKAO YAMAZAKI,

More information

Long-term blood pressure monitoring and echocardiographic findings in patients with end-stage renal disease: reverse epidemiology explained?

Long-term blood pressure monitoring and echocardiographic findings in patients with end-stage renal disease: reverse epidemiology explained? O R I G I N A L A R T I C L E Long-term blood pressure monitoring and echocardiographic findings in patients with end-stage renal disease: reverse epidemiology explained? H. Borsboom 1#, L. Smans 1#, M.J.M.

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter

More information

Appendix 1: Supplementary tables [posted as supplied by author]

Appendix 1: Supplementary tables [posted as supplied by author] Appendix 1: Supplementary tables [posted as supplied by author] Table A. International Classification of Diseases, Ninth Revision, Clinical Modification Codes Used to Define Heart Failure, Acute Myocardial

More information

LEFT VENTRICULAR HYPERTROPHY AND CLINICAL OUTCOME IN CAPD PATIENTS

LEFT VENTRICULAR HYPERTROPHY AND CLINICAL OUTCOME IN CAPD PATIENTS Peritoneal Dialysis International, Vol. 20, pp. 461 466 Printed in Canada. All rights reserved. 0896-8608/00 $3.00 +.00 Copyright 2000 International Society for Peritoneal Dialysis LEFT VENTRICULAR HYPERTROPHY

More information

Cardiac disease is well known to be the leading cause

Cardiac disease is well known to be the leading cause Coronary Artery Bypass Grafting in Who Require Long-Term Dialysis Leena Khaitan, MD, Francis P. Sutter, DO, and Scott M. Goldman, MD Main Line Cardiothoracic Surgeons, Lankenau Hospital, Jefferson Health

More information

Normal kidneys filter large amounts of organic

Normal kidneys filter large amounts of organic ORIGINAL ARTICLE - NEPHROLOGY Effect Of Lanthanum Carbonate vs Calcium Acetate As A Phosphate Binder In Stage 3-4 CKD- Treat To Goal Study K.S. Sajeev Kumar (1), M K Mohandas (1), Ramdas Pisharody (1),

More information

CKD FOR INTERNISTS. Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College

CKD FOR INTERNISTS. Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College CKD FOR INTERNISTS Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College INTRODUCTION In 2002, the National Kidney Foundation s Kidney Disease Outcomes Quality Initiative(KDOQI)

More information

Transient Ischemic Attacks and Risk of Stroke in an Elderly Poor Population

Transient Ischemic Attacks and Risk of Stroke in an Elderly Poor Population Transient Ischemic Attacks and Risk of Stroke in an Elderly Poor Population BY A. M. OSTFELD, M.D., R. B. SHEKELLE, Ph.D., AND H. L. KLAWANS, M.D. Abstract: Transient Ischemic A t tacks and Risk of Stroke

More information

Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD

Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Mun K. Hong, MD Associate Professor of Medicine Director, Cardiovascular Intervention and Research Weill Cornell

More information

DUKECATHR Dataset Dictionary

DUKECATHR Dataset Dictionary DUKECATHR Dataset Dictionary Version of DUKECATH dataset for educational use that has been modified to be unsuitable for clinical research or publication (Created Date and Time: 28OCT16 14:35) Table of

More information

Preoperative risk factors for carotid endarterectomy: Defining the patient at high risk

Preoperative risk factors for carotid endarterectomy: Defining the patient at high risk Preoperative risk factors for carotid endarterectomy: Defining the patient at high risk Amy B. Reed, MD, a Peter Gaccione, MA, b Michael Belkin, MD, b Magruder C. Donaldson, MD, b John A. Mannick, MD,

More information

4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for

4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for + Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics

More information

The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure

The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure Nephrol Dial Transplant (2002) 17: 340 345 The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure Naseem Amin Genzyme Corporation, Cambridge, MA,

More information

Lecture 8 Cardiovascular Health Lecture 8 1. Introduction 2. Cardiovascular Health 3. Stroke 4. Contributing Factors

Lecture 8 Cardiovascular Health Lecture 8 1. Introduction 2. Cardiovascular Health 3. Stroke 4. Contributing Factors Lecture 8 Cardiovascular Health 1 Lecture 8 1. Introduction 2. Cardiovascular Health 3. Stroke 4. Contributing Factors 1 Human Health: What s Killing Us? Health in America Health is the U.S Average life

More information

Utility of Exercise-Induced Zero TBI Sign in Patients on Maintenance Hemodialysis

Utility of Exercise-Induced Zero TBI Sign in Patients on Maintenance Hemodialysis 2016 Annals of Vascular Diseases doi:10.3400/avd.oa.16-00074 Original Article Utility of Exercise-Induced Zero TBI Sign in Patients on Maintenance Hemodialysis Kazuo Tsuyuki, CVT, PhD, 1 Kenji Kohno, PhD,

More information

Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients

Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients Kidney International, Vol. 65 (2004), pp. 626 633 Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients SUYING LI and ALLAN J. COLLINS Nephrology

More information

Objectives. Systolic Heart Failure: Definitions. Heart Failure: Historical Perspective 2/7/2009

Objectives. Systolic Heart Failure: Definitions. Heart Failure: Historical Perspective 2/7/2009 Objectives Diastolic Heart Failure and Indications for Echocardiography in the Asian Population Damon M. Kwan, MD UCSF Asian Heart & Vascular Symposium 02.07.09 Define diastolic heart failure and differentiate

More information

Lnformation Coverage Guidance

Lnformation Coverage Guidance Lnformation Coverage Guidance Coverage Indications, Limitations, and/or Medical Necessity Abstract: B-type natriuretic peptide (BNP) is a cardiac neurohormone produced mainly in the left ventricle. It

More information

Chronic kidney disease (CKD) has received

Chronic kidney disease (CKD) has received Participant Follow-up in the Kidney Early Evaluation Program (KEEP) After Initial Detection Allan J. Collins, MD, FACP, 1,2 Suying Li, PhD, 1 Shu-Cheng Chen, MS, 1 and Joseph A. Vassalotti, MD 3,4 Background:

More information

Cardiovascular Diseases and Diabetes

Cardiovascular Diseases and Diabetes Cardiovascular Diseases and Diabetes LEARNING OBJECTIVES Ø Identify the components of the cardiovascular system and the various types of cardiovascular disease Ø Discuss ways of promoting cardiovascular

More information

Peripheral Arterial Occlusive Disease- The Challenge in patients with diabetes

Peripheral Arterial Occlusive Disease- The Challenge in patients with diabetes Peripheral Arterial Occlusive Disease- The Challenge in patients with diabetes Ashok Handa Reader in Surgery and Consultant Surgeon Nuffield Department of Surgery University of Oxford Introduction Vascular

More information

Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use

Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use Baseline characteristics Users (n = 28) Non-users (n = 32) P value Age (years) 67.8 (9.4) 68.4 (8.5)

More information

patient characteriuics Chapter Two introduction 58 increasing complexity of the patient population 60 epo use & anemia in the pre-esrd period 62

patient characteriuics Chapter Two introduction 58 increasing complexity of the patient population 60 epo use & anemia in the pre-esrd period 62 introduction 58 < increasing complexity of the patient population 6 < epo use & anemia in the pre-esrd period 62 < biochemical & physical characteristics at initiation 64 < estimated gfr at intiation &

More information

The American Experience

The American Experience The American Experience Jay F. Piccirillo, MD, FACS, CPI Department of Otolaryngology Washington University School of Medicine St. Louis, Missouri, USA Acknowledgement Dorina Kallogjeri, MD, MPH- Senior

More information

Supplement materials:

Supplement materials: Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction

More information

Benefits from angiotensin-converting enzyme inhibition in patients with renal failure: latest results

Benefits from angiotensin-converting enzyme inhibition in patients with renal failure: latest results European Heart Journal Supplements (2003) 5 (Supplement E), E18 E22 Benefits from angiotensin-converting enzyme inhibition in patients with renal failure: latest results B. Pannier, A.P. Guérin, S.J. Marchais

More information

Management of Hypertension

Management of Hypertension Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal

More information

Total risk management of Cardiovascular diseases Nobuhiro Yamada

Total risk management of Cardiovascular diseases Nobuhiro Yamada Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible

More information

Acute Coronary Syndrome

Acute Coronary Syndrome ACUTE CORONOARY SYNDROME, ANGINA & ACUTE MYOCARDIAL INFARCTION Administrative Consultant Service 3/17 Acute Coronary Syndrome Acute Coronary Syndrome has evolved as a useful operational term to refer to

More information

Advances in Peritoneal Dialysis, Vol. 29, 2013

Advances in Peritoneal Dialysis, Vol. 29, 2013 Advances in Peritoneal Dialysis, Vol. 29, 2013 Takeyuki Hiramatsu, 1 Takahiro Hayasaki, 1 Akinori Hobo, 1 Shinji Furuta, 1 Koki Kabu, 2 Yukio Tonozuka, 2 Yoshiyasu Iida 1 Icodextrin Eliminates Phosphate

More information

ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM. General Instructions: ID NUMBER: FORM NAME: H F A DATE: 10/13/2017 VERSION: CONTACT YEAR NUMBER:

ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM. General Instructions: ID NUMBER: FORM NAME: H F A DATE: 10/13/2017 VERSION: CONTACT YEAR NUMBER: ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM General Instructions: The Heart Failure Hospital Record Abstraction Form is completed for all heart failure-eligible cohort hospitalizations. Refer to

More information

Antithrombotic therapy in patients with transient ischemic attack / stroke (acute phase <48h)

Antithrombotic therapy in patients with transient ischemic attack / stroke (acute phase <48h) Antithrombotic therapy in patients with transient ischemic attack / stroke (acute phase

More information

THE FRAMINGHAM STUDY Protocol for data set vr_soe_2009_m_0522 CRITERIA FOR EVENTS. 1. Cardiovascular Disease

THE FRAMINGHAM STUDY Protocol for data set vr_soe_2009_m_0522 CRITERIA FOR EVENTS. 1. Cardiovascular Disease THE FRAMINGHAM STUDY Protocol for data set vr_soe_2009_m_0522 CRITERIA FOR EVENTS 1. Cardiovascular Disease Cardiovascular disease is considered to have developed if there was a definite manifestation

More information

The CARI Guidelines Caring for Australasians with Renal Impairment. Serum phosphate GUIDELINES

The CARI Guidelines Caring for Australasians with Renal Impairment. Serum phosphate GUIDELINES Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Serum phosphate GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions

More information

Supplementary material 1. Definitions of study endpoints (extracted from the Endpoint Validation Committee Charter) 1.

Supplementary material 1. Definitions of study endpoints (extracted from the Endpoint Validation Committee Charter) 1. Rationale, design, and baseline characteristics of the SIGNIFY trial: a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical

More information

The cardiologist s interest in renal function

The cardiologist s interest in renal function ASSESSING CARDIOVASCULAR RISK IN PATIENTS WITH CHRONIC KIDNEY DISEASE Jeffrey Brinker, MD* ABSTRACT The manifestations of cardiovascular disease (CVD) in patients with chronic kidney disease (CKD) are

More information

Left Ventricular Diastolic Dysfunction in South Indian Essential Hypertensive Patient

Left Ventricular Diastolic Dysfunction in South Indian Essential Hypertensive Patient Left Ventricular Diastolic Dysfunction in South Indian Essential Hypertensive Patient Dr. Peersab.M. Pinjar 1, Dr Praveenkumar Devarbahvi 1 and Dr Vasudeva Murthy.C.R 2, Dr.S.S.Bhat 1, Dr.Jayaraj S G 1

More information

Antihypertensive Trial Design ALLHAT

Antihypertensive Trial Design ALLHAT 1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes

More information